Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 2
2017 2
2020 1
2022 2
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
Chlebowski RT, Aragaki AK, Pan K, Mortimer JE, Johnson KC, Wactawski-Wende J, LeBoff MS, Lavasani S, Lane D, Nelson RA, Manson JE. Chlebowski RT, et al. Among authors: lavasani s. Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38653905
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer.
Mahin D, Lavasani SM, Cristobal L, Tank Patel N, Sedrak M, Stewart D, Waisman J, Yuan Y, Yu W, Samoa R, Ruel N, Yost SE, Lee H, Kil SH, Mortimer JE. Mahin D, et al. Among authors: lavasani sm. J Clin Med. 2023 Feb 28;12(5):1906. doi: 10.3390/jcm12051906. J Clin Med. 2023. PMID: 36902693 Free PMC article.
Surviving Burnout as an Oncologist.
Lavasani S. Lavasani S. Curr Oncol Rep. 2023 Feb;25(2):131-134. doi: 10.1007/s11912-022-01351-8. Epub 2023 Jan 10. Curr Oncol Rep. 2023. PMID: 36626037 Review.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative.
Brasky TM, Krok-Schoen JL, Liu J, Chlebowski RT, Freudenheim JL, Lavasani S, Margolis KL, Qi L, Reding KW, Shields PG, Simon MS, Wactawski-Wende J, Wang A, Womack C, Manson JE. Brasky TM, et al. Among authors: lavasani s. Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1345-1348. doi: 10.1158/1055-9965.EPI-17-0096. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 28765339 Free PMC article.
16 results